These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12964893)

  • 1. Transdermal oxybutynin. A viewpoint by Michael Chancellor.
    Chancellor M
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964893
    [No Abstract]   [Full Text] [Related]  

  • 2. Transdermal oxybutynin. A viewpoint by Adrian Wagg.
    Wagg A
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964894
    [No Abstract]   [Full Text] [Related]  

  • 3. Oxybutynin transdermal (Oxytrol) for overactive bladder.
    Med Lett Drugs Ther; 2003 May; 45(1156):38-9. PubMed ID: 12736598
    [No Abstract]   [Full Text] [Related]  

  • 4. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal oxybutynin: for overactive bladder.
    Bang LM; Easthope SE; Perry CM
    Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 8. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
    Lose G; Nørgaard JP
    BJU Int; 2001 Jun; 87(9):767-73. PubMed ID: 11412211
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.
    Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW;
    J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
    Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW
    World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study.
    Goldfischer ER; Sand PK; Thomas H; Peters-Gee J
    Neurourol Urodyn; 2015 Jan; 34(1):37-43. PubMed ID: 24133005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 16. [Instability of the detrusor muscle. Treatment with oxybutynin chloride (ditropan)].
    Perales Cabanas L; Tallada Buñuel M; Romero Maroto J; Escribano Patiño G
    Actas Urol Esp; 1986; 10(6):481-6. PubMed ID: 3825651
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
    Halaska M; Ralph G; Wiedemann A; Primus G; Ballering-Brühl B; Höfner K; Jonas U
    World J Urol; 2003 May; 20(6):392-9. PubMed ID: 12811500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in medical management of overactive bladder.
    Richelson E; Elliott DS
    Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
    [No Abstract]   [Full Text] [Related]  

  • 20. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.